Marinus Pharmaceuticals’ (MRNS) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Thursday morning,Benzinga reports. The brokerage currently has a $2.00 target price on the biopharmaceutical company’s stock.

Several other brokerages have also issued reports on MRNS. Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. Royal Bank of Canada reduced their price objective on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research report on Friday, October 25th. TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Finally, Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a research report on Monday, September 23rd. Nine investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Marinus Pharmaceuticals has an average rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ:MRNS opened at $0.30 on Thursday. Marinus Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $11.26. The firm has a market capitalization of $16.66 million, a P/E ratio of -0.12 and a beta of 1.26. The stock has a 50 day moving average price of $1.22 and a 200-day moving average price of $1.31.

Institutional Trading of Marinus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in MRNS. Vanguard Group Inc. boosted its stake in Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after purchasing an additional 132,689 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Marinus Pharmaceuticals by 31.4% in the 1st quarter. Avoro Capital Advisors LLC now owns 4,140,607 shares of the biopharmaceutical company’s stock worth $37,431,000 after buying an additional 990,607 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Marinus Pharmaceuticals in the 1st quarter worth $384,000. SG Americas Securities LLC purchased a new position in shares of Marinus Pharmaceuticals in the 2nd quarter worth $34,000. Finally, Values First Advisors Inc. boosted its stake in shares of Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 52,257 shares during the last quarter. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.